India will receive 60-70 million doses of the Covishield vaccine from Oxford by December, but the vaccines will hit the market in March 2021, the Serum Institute of India (SII) in Pune said, revealing its latest updates on the ongoing trial of the Astrazeneca-Oxford vaccine. Time between December and March will be needed for licensing, said Dr. Suresh Jadav, SII Executive Director, who participated in the HEAL-Thy Samvaad India Vaccine Accessibility Electronic Summit, organized by an NGO.
Once it is released, the world’s largest vaccine company by the number of doses produced will continue to make more vaccines.
IBS is currently conducting Phase 2 and 3 trials of the vaccine. Reports say the vaccine maker wants to be more inclusive when it comes to the variety of participants. The pharmaceutical company wants to cover the elderly and people with health problems.
The logistical preparation for the Covid-19 vaccine is in full swing. The Center had previously asked states to prioritize the populations that should receive the vaccine, once registered, first. Prime Minister Narendra Modi has held back-to-back review meetings and called on government officials to ensure speedy delivery of vaccines. In a meeting on Saturday, Prime Minister Modi suggested taking the help of the election mechanism to ensure the administration of vaccines.
The government aims to vaccinate approximately 25 million people by July 2021. This will include the three vaccines currently being tested in India and also those that India will obtain under other agreements, such as the WHO COVAX, Dr. Reddy’s agreement with Russia for Sputnik. V etc.
.
